In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
Action Alert: Support Gynecologic Cancer Initiatives for FY2027
On March 17, Ovarian Cancer Research Alliance (OCRA) Advocate Leaders from across the country will be on Capitol Hill for OCRA’s Spring Advocacy Day—and we need your voice, too. If you can’t join us in person, please take action to reinforce our efforts on the Hill and help us make a big impact. Advocacy Day Priorities This … Continued
Cool Hand Frank Names OCRA Featured Cause for March
Cool Hand Frank, a digital publication that spotlights nonprofits making a difference, has named Ovarian Cancer Research Alliance (OCRA) its featured cause for March 2026, spotlighting OCRA’s work in advancing ovarian and gynecologic cancer research and supporting patients and their loved ones. The publication cited a deeply personal connection to the cause, with the author … Continued
New AI Accelerator Grant Captures Health and Science Media Attention
OCRA is excited to see the work fueled by our new AI Accelerator Grant resonating with a broad array of audiences. Since the Global Ovarian Cancer Research Consortium announced the inaugural AI Accelerator Grant on February 19, coverage has appeared across health, science, and business media outlets. The $1 million global research award—with an additional … Continued